<DOC>
	<DOC>NCT02223013</DOC>
	<brief_summary>Comparative pharmacokinetics and tolerability of two experimental extended release formulations and a standard formulation of BIBV 308 SE following multiple doses.</brief_summary>
	<brief_title>Relative Bioavailability and Tolerability of Two New Different Extended Release Capsules of BIBV 308 SE, Versus a Solution of BIBV 308 SE in Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>Subjects that were previously entered in at least one BIBV 308 SE study to ensure that it is known how these subjects absorb BIBV 308 SE Healthy subjects as determined by results of screening Signed written informed consent in accordance with Good Clinical Practice (GCP) and local legislation Age &gt;= 18 and &lt;= 55 years Broca &gt;= 20% and &lt;= +20 % Poor individual absorption kinetics of BIBV 308 SE in previous studies Any findings of the medical examination (including blood pressure, pulse rate and Electrocardiogram (ECG)) deviating from normal and of clinical relevance Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal (including thyroid) disorders Surgery of the gastrointestinal tract (except appendectomy) Diseases of the central nervous system (such as epilepsy) or psychiatric disorders Chronic or acute relevant infections History of allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged by the investigator Hypersensitivity to BIBV 308 SE and any of the excipients Intake of drugs with a long halflife (&gt; 24 hours) &lt;= 1 month prior to administration or during the trial Use of any drugs which might influence the results of the trial &lt;= 10 days prior to administration or during the trial Participation in another trial with an investigational drug &lt;= 2 months days prior to administration or during the trial Smoker (&gt; 10 cigarettes or &gt; 3 cigars or &gt; 3 pipes/day) Inability to refrain from smoking during the period of the study Known alcohol (&gt; 60 g/day) or drug abuse Blood donation (&lt;= 1 month prior to administration) Excessive physical activities (&lt;= 5 days prior to administration) Any laboratory value outside the normal range of clinical relevance History of haemorrhagic diathesis History of gastrointestinal ulcer, perforation or bleeding History of bronchial asthma</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>